Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01610440
Recruitment Status : Unknown
Verified November 2012 by Shenzhen Beike Bio-Technology Co., Ltd..
Recruitment status was:  Recruiting
First Posted : June 4, 2012
Last Update Posted : November 30, 2012
Sponsor:
Collaborator:
The Second Affiliated Hospital of Kunming Medical University
Information provided by (Responsible Party):
Shenzhen Beike Bio-Technology Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Duchenne muscular dystrophy (DMD), an X-linked recessive genetic disease always progressed slowly，tends to leading proximal skeletal muscle atrophy and weakness of limbs, as well as impaired respiratory muscle and cardiac muscle. To a large extent, patients always lose motor function gradually and die for heart failure or severe infection at the end stage of DMD. At present, the treatment strategy relies on heteropathy accompanied with rehabilitation training. However, the therapeutic effect remains extremely limited.

Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been evidenced to improve motor function, increase muscle strength and reduce abnormal levels of related enzymes, such as creatine kinase (CK), lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This study is aimed to explore the safety and efficacy of hUC-MSCs transplantation for DMD.


Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Biological: human umbilical cord mesenchymal stem cells Phase 1 Phase 2

Detailed Description:
This study is designed to investigate the safety and efficacy of human umbilical cord mesenchymal stem cells transplantation in patients with progressive muscular dystrophy.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Stem Cell Therapy in Patients With Duchenne Muscular Dystrophy
Study Start Date : October 2011
Estimated Primary Completion Date : March 2013
Estimated Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention Group
Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
 Biological: human umbilical cord mesenchymal stem cells
rehabilitation therapy plus human umbilical cord mesenchymal stem cells


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Activities of Daily Living(ADL)scale [ Time Frame: 1 year after treatment ]

Secondary Outcome Measures :
  1. Incidences of Adverse Event and Serious Adverse Event [ Time Frame: 1 year after treatment ]
  2. Change from baseline in CK [ Time Frame: 1 year after treatment ]
  3. Change from baseline in LDH [ Time Frame: 1 year after treatment ]
  4. Change from baseline in ALT [ Time Frame: 1 year after treatment ]
  5. Change from baseline in AST [ Time Frame: 1 year after treatment ]
  6. Change from baseline to manual muscle test(MMT) [ Time Frame: 1 year after treatment ]
  7. Change from baseline in electromyography(EMG) [ Time Frame: 1 year after treatment ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 5-12 years
  • Clinical manifestation, enzymology, electromyogram, gene type confirmed the diagnose of Duchenne muscular dystrophy
  • Sign the consent form and follow the clinic trail procedure

Exclusion Criteria:

  • Not Duchenne muscular dystrophy
  • Any history of hypersensitivity to serum products,or other know drug and food allergy
  • Combined Pneumonia or other Severe systemic bacteria infection
  • HIV+, TPPA +， patients diagnosed as HBV or HCV
  • Tumor Markers +
  • Severe psychotic patients, cognitive dysfunction
  • Coagulation disorders
  • Uncontrolled hypertension after treatment，blood pressure≥180mmHg/110 mmHg
  • Other severe systemic or organic disease
  • Enrollment in other trials in the last 3 months
  • Received any stem cell therapy in past 6 months
  • Other criteria that investigator consider improper for inclusion
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01610440


Contacts
Layout table for location contacts
Contact: Liqing Yao yaoliqing98731@yahoo.com.cn

Locations
Layout table for location information
China, Yunnan
The Second Affiliated Hospital of Kunming Medical College Recruiting
Kunming, Yunnan, China, 650031
Contact: Liqing Yao       yaoliqing98731@yahoo.com.cn   
Principal Investigator: Liqing Yao         
Sponsors and Collaborators
Shenzhen Beike Bio-Technology Co., Ltd.
The Second Affiliated Hospital of Kunming Medical University
Investigators
Layout table for investigator information
Principal Investigator: Liqing Yao The Second Affiliated Hospital of Kunming Medical University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Shenzhen Beike Bio-Technology Co., Ltd.
ClinicalTrials.gov Identifier: NCT01610440    
Other Study ID Numbers: BKCR-DMD-1(Ⅰ)
First Posted: June 4, 2012    Key Record Dates
Last Update Posted: November 30, 2012
Last Verified: November 2012
Keywords provided by Shenzhen Beike Bio-Technology Co., Ltd.:
Duchenne muscular dystrophy
Human Umbilical Cord Mesenchymal Stem Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
 Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked